Table 3.
Summary of metabolic, haemodynamic and volume-related biochemical changes from baseline at week 104
| Variable | Treatment group | n | LSM (95% CI) | Difference vs non-ertugliflozin | |
|---|---|---|---|---|---|
| LSM (95% CI) | p valuea | ||||
| HbA1c, mmol/mol | Non-ertugliflozin | 417 | −6.84 (−7.65, −6.03) | ||
| Ertugliflozin 5 mg | 420 | −6.84 (−7.64, −6.03) | 0.0 (−1.14, 1.14) | >0.99 | |
| Ertugliflozin 15 mg | 428 | −7.74 (−8.54, −6.94) | −0.90 (−2.04, −0.23) | 0.12 | |
| HbA1c (%) | Non-ertugliflozin | 417 | −0.63 (−0.70, −0.55) | ||
| Ertugliflozin 5 mg | 420 | −0.63 (−0.70, −0.55) | 0.0 (−0.10, 0.10) | >0.99 | |
| Ertugliflozin 15 mg | 428 | −0.71 (−0.78, −0.64) | −0.08 (−0.19, −0.02) | 0.12 | |
| Fasting plasma glucose, mmol/l | Non-ertugliflozin | 409 | −0.73 (−0.89, −0.58) | ||
| Ertugliflozin 5 mg | 410 | −1.07 (−1.22, −0.92) | −0.34 (−0.55, −0.12) | <0.01 | |
| Ertugliflozin 15 mg | 428 | −1.33 (−1.48, −1.18) | −0.60 (−0.81, −0.38) | <0.001 | |
| Weight, kg | Non-ertugliflozin | 421 | 0.65 (0.35, 0.95) | ||
| Ertugliflozin 5 mg | 419 | −3.24 (−3.54, −2.94) | −3.89 (−4.31, −3.47) | <0.001 | |
| Ertugliflozin 15 mg | 431 | −3.48 (−3.77, −3.18) | −4.13 (−4.55, −3.71) | <0.001 | |
| Systolic BP, mmHg | Non-ertugliflozin | 413 | 1.70 (0.64, 2.75) | ||
| Ertugliflozin 5 mg | 415 | −2.81 (−3.86, −1.75) | −4.50 (−6.00, −3.02) | <0.001 | |
| Ertugliflozin 15 mg | 426 | −1.82 (−2.86, −0.78) | −3.52 (−5.00, −2.04) | <0.001 | |
| Diastolic BP, mmHg | Non-ertugliflozin | 413 | 0.24 (−0.43, 0.90) | ||
| Ertugliflozin 5 mg | 415 | −1.61 (−2.28, −0.95) | −1.85 (−2.79, −0.91) | <0.001 | |
| Ertugliflozin 15 mg | 426 | −0.49 (−1.15, 0.16) | −0.73 (−1.67, 0.20) | 0.12 | |
| Pulse rate, beats/min | Non-ertugliflozin | 413 | 0.25 (−0.46, 0.95) | ||
| Ertugliflozin 5 mg | 414 | −0.41 (−1.11, 0.30) | −0.66 (−1.65, 0.34) | 0.20 | |
| Ertugliflozin 15 mg | 426 | 0.35 (−0.35, 1.04) | 0.10 (−0.89, 1.09) | 0.85 | |
| Haematocrit, proportion of 1.0 | Non-ertugliflozin | 393 | 0.00 (−0.00, 0.00) | ||
| Ertugliflozin 5 mg | 403 | 0.02 (0.02, 0.02) | 0.02 (0.02, 0.02) | <0.001 | |
| Ertugliflozin 15 mg | 410 | 0.02 (0.02, 0.03) | 0.02 (0.02, 0.03) | <0.001 | |
| Haemoglobin, g/l | Non-ertugliflozin | 407 | −0.14 (−0.95, 0.67) | ||
| Ertugliflozin 5 mg | 412 | 6.22 (5.41, 7.03) | 6.36 (5.22, 7.51) | <0.001 | |
| Ertugliflozin 5 mg | 424 | 7.13 (6.33, 7.92) | 7.26 (6.13, 8.40) | <0.001 | |
| Albumin, g/l | Non-ertugliflozin | 407 | −0.47 (−0.67, −0.27) | ||
| Ertugliflozin 5 mg | 402 | 0.00 (−0.21, 0.20) | 0.47 (0.18, 0.76) | <0.01 | |
| Ertugliflozin 15 mg | 417 | 0.03 (−0.17, 0.23) | 0.50 (0.20, 0.79) | <0.001 | |
| Uric acid, μmol/l | Non-ertugliflozin | 406 | 15.50 (9.95, 21.06) | ||
| Ertugliflozin 5 mg | 402 | −28.76 (−34.33, −23.19) | −44.27 (−52.13, −36.40) | <0.001 | |
| Ertugliflozin 15 mg | 417 | −34.57 (−40.04, −29.10) | −50.07 (−57.87, −42.28) | <0.001 | |
aTesting the difference between the ertugliflozin and non-ertugliflozin groups